Newsroom

The Anoche tuve un sueño magazine awarded Dr. Albert Quintana for his project to create a kit to detect antibiotic resistance.

The Neurodocs Student Association organized a calçotada last April 6, which brought together around 30 members of the Institute.

The Institute has signed a collaboration agreement with AdSalutem, a reference center in sleep medicine and brain health. The idea of ¿¿the agreement is to promote collaborations between INc-UAB groups and professionals from the centre.

Researchers at the Institute have carried out two revealing studies on TRPV2, a key ion channel in several cellular functions, which points to it as a possible new therapeutic target in the treatment of hypertension. On the one hand, they have discovered the vessel-dilating effects of its activation and, on the other, they have identified a molecule capable of activating it in a more potent way than the drugs known to date.

A research team led by Dr Esther Dalfó has managed to generate and validate a new animal model.  This model enables the examination of the initial phases of Parkinson's disease, occurring prior to the onset of motor symptoms, and the exploration of molecular processes preceding neuronal degeneration. The new model, based on the Caenorhabditis elegans worm, emerges as an essential tool in creating future therapies aimed at stopping the characteristic loss of neuronal structure and function seen in the disease.

A study coordinated by Dr. Jiménez-Altayó demonstrates in animal models the benefits of vorinostat after having suffered a stroke. The drug, used in humans to treat cutaneous T-cell lymphoma, has been proved to mitigate brain injuries and help in restoring brain tissue.

Last January 10 and 11, the members of the external evaluation committee visited the Institute and met with the coordinators of the SGRs and members of the different groups. The goal is for them to report on the state of the center and propose improvement initiatives that can be implemented.

A study published in Nature Nanotechnology presents an innovative graphene-based neurotechnology with the potential for a transformative impact in neuroscience and medical applications. This research, spearheaded by the Catalan Institute of Nanoscience and Nanotechnology (ICN2), with the participation of the Institute, is currently being developed for therapeutic applications through the spin-off INBRAIN Neuroelectronics. Read the article

La UAB ha posat en marxa una nova campanya per recaptar fons per estudiar una teràpia gènica per a la deficiència d'adenilsuccinat liasa (ADSL), una malaltia genètica ultrarara que pateixen uns 80 nens i nenes al món, entre els quals dos germans de Cambrils, l’Anton i l’Andreu.

La informació que percebem del moviment viatja des de l'oïda interna fins a unes zones del cervell anomenades nuclis vestibulars, que juguen un paper important en el mareig. Ara, investigadors del grup de recerca en Neuropatologia mitocondrial i la Universitat de Washington han identificat en ratolins quines neurones específiques transmeten els senyals que provoquen aquest malestar. L’estudi s’ha publicat a la revista Proceedings of the National Academy of Sciences (PNAS). Llegeix l'article